November 2015PDF



Keytruda Shows Anti-Tumor Activity in Three Combinations and Phase III Trial

Merck presented three studies investigating the use of Keytruda (pembrolizumab), an anti-PD-1 therapy, in combination with three other immunotherapies—epacadostat, Imlygic (talimogene laherparepvec), and ipilimumab—in patients with advanced melanoma.

Keytruda showed anti-tumor activity in all three combinations studied. The findings were featured in separate oral presentations at the International Congress of the Society for Melanoma Research, in San Francisco.

Additionally, updated data presented from a phase III study of Keytruda as a single agent showed superior overall response rates and progression free survival compared to ipilimumab in ipilimumab-naïve patients, with twice as many patients achieving PFS on Keytruda compared to ipilimumab.

 Drugs and Targets

FDA Approves Ninlaro and Darzalex For the Treatment of Multiple Myeloma

FDA approved Ninlaro (ixazomib), developed by Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. Ixazomib is the first approved oral proteasome inhibitor.

The approval was based on an improvement in progression- free survival in a multicenter, randomized, double-blind, placebo-controlled trial enrolling 722 patients with multiple myeloma who had received one to three prior lines of therapy. Patients were randomized in a 1:1 ratio to either the combination of ixazomib, lenalidomide and dexamethasone (n=360) or the combination of placebo, lenalidomide and dexamethasone (n=362). Patients continued treatment until disease progression or unacceptable toxicity.


Lenalidomide-Rituximab Combination Shows Benefits in Mantle Cell Lymphoma

A combination therapy lacking many of the debilitating effects of traditional cancer treatment effectively manages mantle cell lymphoma, shrinking the malignancy and inducing remissions in the majority of patients, according to new research from Weill Cornell Medicine.

The phase II study demonstrated that lenalidomide, in combination with rituximab, provides an effective alternative to chemotherapy. More than 90 percent of patients in the small efficacy trial responded to the therapy, with their cancer shrinking by more than half, and two-thirds of that group had no evidence of detectable tumor growth after treatment.


ICT-107 Boosts Overall Survival by 10 Percent In Phase II Trial

 Childhood Cancer

Researchers: All Pediatric Patients, Regardless of Family History, Could Benefit from Genomic Screening

 Cancer Genomics

TCGA Researchers Identify 7 Subtypes of Prostate Cancer And 2 Drivers of Papillary RCC

 Lung Cancer

FDA Requests Data from Clovis For Rociletinib NDA in NSCLC

 NCI CTEP-Approved Studies for the Month of November
November 2015
October 2015PDF


 Drugs and Targets

FDA Approves Imlygic as First Oncolytic Viral Therapy in the U.S., for Melanoma

FDA approved Imlygic (talimogene laherparepvec) as the first oncolytic viral therapy in the U.S.

Imlygic, developed by Amgen, is indicated for the local treatment of unresectable cutaneous, subcutaneous and nodal lesions in patients with melanoma recurrent after initial surgery. Imlygic has not been shown to improve overall survival or have an effect on visceral metastases.

Imlygic is a genetically modified herpes simplex virus type 1 designed to replicate within tumors and produce granulocyte-macrophage colony-stimulating factor, an immunostimulatory protein. Imlygic causes cell lysis rupturing tumors and releasing tumor-derived antigens, which along with GM-CSF, may promote an anti-tumor immune response. However, the exact mechanism of action is unknown, according to Amgen.


 Breast Cancer

Phase III Trial Finds Equivalent OS Rates Between APBI Brachytherapy and Whole Breast Irradiation Therapy

A prospective, randomized, multicenter phase III study comparing accelerated partial breast irradiation with interstitial multicatheter brachytherapy to whole breast irradiation showed that APBI brachytherapy lead to equivalent overall survival and local and regional cancer control rates, as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers.

The primary objective of the trial was to assess the role of APBI brachytherapy alone compared to whole breast irradiation with boost in a defined group of patients with invasive (stage I-IIA) breast cancer or ductal carcinoma in situ (stage 0) who underwent breast-conserving surgery.

 Non-Small Cell Lung Cancer

Patients Receiving IMRT Had Less Toxicity Compared to 3D CRT, Study Finds

Patients with locally advanced non-small cell lung cancer that received intensity modulated radiation therapy had less severe lung toxicity and were able to better tolerate their chemotherapy compared to patients who received 3D conformal radiation therapy, according to a secondary analysis of a large phase III trial.

The study, NRG/RTOG 0617, originally enrolled patients from 2007 to 2011, and compared a high dose of 74 Gy to the standard dose of 60 Gy. All underwent concurrent chemotherapy (carboplatin/paclitaxel, with or without cetuximab) and either 3D CRT or IMRT. In the study, 482 patients were treated with radiation—53 percent with IMRT and 47 percent with 3-D CRT.

Prostate Cancer

Phase III Trial Demonstrates Shorter, Hypofractionated RT Can Deliver Similar Results Compared to Conventional RT


WT1 Vaccine Doubles PFS In MPM Patients in Phase II Trial

 Renal Cell Carcinoma

Study: Lenvatinib-Everolimus Combination Can Improve PFS

 Carcinoid Syndrome

Telotristat Etiprate Demonstrates Clinical Benefit in Phase III Study

 Cervical Cancer

Outreach Program Boosts HPV Vaccine Three-Dose Series Completion

 NCI CTEP-Approved Trials For the Month of October
November 2015
September 2015PDF


 Lung Cancer

Avastin Biosimilar Meets Phase III Endpoints, Demonstrating Clinical Equivalence

Amgen and Allergan plc. announced positive top-line results from Avastin biosimilar candidate ABP 215, which met its primary and secondary endpoints in a phase III trial in advanced non-squamous non-small cell lung cancer.

ABP 215 is being developed as a biosimilar to Avastin, a recombinant immunoglobulin G1 monoclonal antibody that binds to vascular endothelial growth factor and inhibits the interaction of VEGF with its receptors, VEGF receptor-1 and VEGF receptor-2.

The primary endpoint, objective response rate, was within the prespecified margin for ABP 215 compared to Avastin (bevacizumab), showing clinical equivalence.

 Neuroendocrine Tumors

Afinitor Extends PFS by 7.1 Months in Gastrointestinal and Lung NETs

Novartis announced results of a phase III study showing Afinitor (everolimus) tablets reduced the risk of progression by 52 percent (HR=0.48; 95% CI, 0.35-0.67; p<0.00001) compared to placebo in patients with advanced, progressive, nonfunctional neuroendocrine tumors of gastrointestinal or lung origin.

The study, RADIANT-4, was presented at the European Cancer Congress in Vienna, Austria.

Additionally, the data show Afinitor, a mammalian target of rapamycin (mTOR) inhibitor, extended median progression free survival by 7.1 months: median PFS by central review was 11.0 months (95% CI, 9.23-13.3) in the Afinitor arm and 3.9 months (95% CI, 3.58-7.43) in the placebo arm.


 Prostate Cancer

Additional Analyses Show Custirsen Lowered Serum Clusterin Levels in CRPC Patients

OncoGenex Pharmaceuticals Inc. presented results from additional exploratory analyses of the phase III SYNERGY trial, demonstrating that custirsen treatment significantly lowered serum clusterin levels from baseline in men with metastatic castrate-resistant prostate cancer.

The data, presented at the 2015 European Cancer Congress in Vienna, Austria, showed that sCLU reductions after custirsen treatment resulted in higher two-year survival rates in patients who were at increased risk for poor outcomes.

Myeloid Malignancies

Two NEJM Papers Evaluate Imetelstat in Myelofibrosis and Essential Thrombocythemia

 Bladder Cancer

Cyramza Increases PFS In Phase II Study of Patients Who Failed Platinum Therapy

 NCI CTEP-Approved Trials For the Month of September
 Drugs and Targets

  • FDA Approves Varubi for CINV
  • FDA Grants Priority Review for MCNA in invasive bladder cancer
  • FDA Grants Priority Review to Kyprolis in relapsed multiple myeloma
October 2015
August 2015PDF



High-Risk Subset of CLL Patients Shows Benefit in Phase II Trial

A statistically significant percentage of chronic lymphocytic leukemia patients in a phase II clinical trial responded to venetoclax therapy.

The open-label study, sponsored by AbbVie, met its primary endpoint, achieving overall response rates in patients with relapsed/refractory or previously untreated CLL with 17p deletion, according to an independent review analysis.

The study enrolled 157 patients, 107 in the main study cohort evaluating efficacy, and 50 patients in the safety expansion cohort.

The primary efficacy endpoint is overall response rate, and the primary safety endpoints are the number and percentage of patients who experienced treatment-related adverse events, changes in physical exam findings, including vital signs, changes in clinical laboratory test results and changes in cardiac assessment findings.


Lung Cancer

Atezolizumab Immunotherapy Meets Response Endpoint in Phase II NSCLC Study

A phase II study of atezolizumab immunotherapy met its primary endpoint, shrinking tumors in patients with locally advanced or metastatic non-small cell lung cancer whose disease expressed PD-L1.

The study showed the amount of PD-L1 expressed by a person’s cancer correlated with their response to the medicine.

The study, BIRCH, is an open-label, multicenter, single-arm study that evaluated the safety and efficacy of atezolizumab in 667 people. Results from the study will be presented at an upcoming medical meeting, according to the drug’s sponsor, Genentech, a member of the Roche Group.



Drugs and Targets

European Commission Approves Unituxin in Pediatric High-Risk Neuroblastoma

The European Commission granted a marketing authorization for Unituxin (dinutuximab) for the treatment of high-risk neuroblastoma in patients aged 12 months to 17 years, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and autologous stem cell transplantation.

Unituxin is administered in combination with granulocyte-macrophage colony-stimulating factor, interleukin-2, and isotretinoin.

The European approval was based on demonstration of improved event-free survival and overall survival in a multicenter, open-label, randomized trial (ANBL0032) sponsored by NCI under a Cooperative Research and Development Agreement with the drug’s sponsor, United Therapeutics Corp., and conducted by the Children’s Oncology Group.


Liver Cancer

ThermoDox plus RFA Increase OS By 58 Percent in HEAT Study


Carcinoid Syndrome

Oral Telotristat Etiprate Trial Meets Phase III Primary Endpoint


NCI CTEP-Approved Trials for the Month of August

August 2015
July 2015PDF



Phase II Trial Shows Benefit with Imbruvica In Activated B-cell-like Subtype of DLBCL

A phase II clinical trial identified patients with a specific molecular subtype of diffuse large B-cell lymphoma that are more likely to respond to Imbruvica (ibrutinib) treatment.

In the trial, patients with the activated B-cell-like subtype of DLBCL were more likely to respond to Imbruvica than patients with the germinal center B-cell-like subtype. The trial was jointly conducted by NCI and Pharmacyclics Inc., and was published in Nature Medicine.


Drugs and Targets

FDA Approves Odomzo in Advanced BCC, Kyprolis Combination in Multiple Myeloma

FDA approved Odomzo (sonidegib) capsules for the treatment of patients with locally advanced basal cell carcinoma that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy. Odomzo is marketed by Novartis Pharmaceuticals Corp.

The approval was based on demonstration of a durable objective response rate in an international, multi-center, double-blind, randomized, two-arm, non-comparative trial in patients with locally advanced basal cell carcinoma not amenable to local therapy or metastatic basal cell carcinoma.


Prostate Cancer

Researchers: As Many as 40% of Patients Could be Receiving Overtreatment

As many as 40 percent of patients with lower-risk prostate cancers may be currently receiving overtreatment, according to researchers that examined common treatment practices.

Monitoring men with very low- and low-risk prostate cancers using watchful waiting or active surveillance, or expectant management, is a useful approach for a large number of men with localized tumors and could spare them the debilitating side effects of aggressive treatments that are too often unnecessarily used in this patient population, according to a study led by researchers at UCLA.


Colorectal Cancer

Vectibix Improves OS in Phase III Trial of mCRC


Liver Cancer

Cyramza Trial Fails OS Endpoint; Subgroup Data to Form New Study



Pracinostat/Vidaza Combination Shows Response in Phase II Trial


Bladder Cancer

Study: Robotic Surgery Shows Long-term Results Similar to Traditional Open Surgery


NCI CTEP-Approved Trials for the Month of July

August 2015
June 2015PDF



Adding Imbruvica to Bendamustine/Rituximab Combination Increases PFS in Phase III Trial

Patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma that received Imbruvica (ibrutinib) in combination with bendamustine and rituximab experienced an 80 percent reduction in the risk of progression or death when compared to patients receiving bendamustine, rituximab and placebo in a phase III trial.

Imbruvica patients also experienced a higher overall response rate, including achieving a higher rate of complete responses, after a median follow-up of 17 months.
On March 16, an independent data monitoring committee recommended that the trial, named HELIOS, be unblinded based on clinically meaningful and statistically significant treatment benefit observed in the Imbruvica arm compared to placebo and BR.



Trial: Tafinlar/Mekinist Combination Benefits BRAF V600E/K Mutation-Positive Patients

Data from the phase III COMBI-d study showed a significant survival benefit for patients with BRAF V600E/K mutation-positive metastatic melanoma when treated with the combination of Tafinlar and Mekinist compared to Tafinlar alone.

The final analysis included the 423 patients enrolled in COMBI-d and showed that the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) achieved a statistically significant overall survival benefit compared to Tafinlar monotherapy, with median of 25.1 months compared to 18.7 months, respectively (HR=0.71 [95% CI, 0.55-0.92], p=0.011).


Lung Cancer

Gilotrif Reduces Risk of Death by 19 Percent In Phase III Squamous Cell Carcinoma Trial

Overall survival results from the LUX-Lung 8 trial comparing two EGFR-directed treatments, Gilotrif (afatinib) and Tarceva (erlotinib), in patients with advanced squamous cell carcinoma of the lung progressing after treatment with first-line chemotherapy, demonstrated that treatment with Gilotrif significantly reduced the risk of death by 19 percent, extending the survival of patients to a median of 7.9 months compared to 6.8 months on Tarceva.

Significantly more patients treated with Gilotrif were still alive at one year compared to those treated with Tarceva (36.4 vs. 28.2 percent).


Prostate Cancer

Retrospective Analysis Shows Benefit with Custirsen in mCRPC Patients with Poor Prognosis



Pacritinib Demonstrates Control Of Symptoms in Phase III Trial


Kidney Cancer

Phase II Study Compares Afinitor As Second-Line Treatment Following Various VEGFR Inhibitors and Cytokine Therapy


Pancreatic Cancer

PEGPH20 Shows Doubling of PFS Among Patients with High Levels Of Hyaluronan in Phase II Trial


Breast Cancer

Phase III Prolia Trial Meets Endpoint in Clinical Fractures



Electric Nerve Stimulation Shown to Be as Effective as Pilocarpine in Treating Radiation-Induced Dry Mouth


Drugs and Targets

Lenvatinib Launched in U.K. For Advanced Thyroid Cancer

 NCI CTEP-Approved Trials for the Month of June
June 2015
May 2015PDF


NCI MATCH Trial to Begin Patient Enrollment in July

CHICAGO—NCI’s long-planned, large scale precision medicine trial will open to patient enrollment in July, investigators announced June 1 at the annual meeting of the American Society of Clinical Oncology.

NCI-MATCH: Molecular Analysis for Therapy Choice will assign patients to therapies based on molecular profiles of their tumors, rather than the organ site where their cancer began. The purpose is to determine whether targeted therapies for people whose tumors have specific gene mutations will be effective regardless of their cancer type.

The phase II trial will incorporate more than 20 different study drugs or drug combinations, each targeting a specific gene mutation, to match each patient with a therapy that targets a molecular abnormality in their tumor.


ASCO to Launch its First Clinical Trial: TAPUR

CHICAGO—The American Society of Clinical Oncology announced June 1 that it will move forward with its first-ever clinical trial, a study designed to offer patients with advanced cancer access to molecularly-targeted cancer drugs and to collect data on clinical outcomes to learn the best uses of these drugs outside of FDA-approved indications.

The Targeted Agent and Profiling Utilization Registry, or TAPUR, is a prospective, non-randomized clinical trial that will collect information on the anti-tumor activity and toxicity of commercially available, targeted cancer drugs in a range of cancer types, including any advanced solid tumor, multiple myeloma, or non-Hodgkin lymphoma with a genomic variation known to be a drug target.


Pancreatic Cancer

IMM-101 Combination Improves OS in Metastatic Disease in Phase II Trial

Updated long-term survival results from IMAGE 1, a phase II clinical trial evaluating a combination of IMM-101 and gemcitabine as first-line treatment for advanced pancreatic cancer, found that, in patients with metastatic disease, IMM-101 was associated with improving the probability of survival at 12 months to 24 percent, compared to 11.5 percent in patients receiving gemcitabine alone.

This difference was amplified at 18 months to 18.3 percent for IMM-101-treated patients compared to 2.3 percent in the control group. At 24 months the corresponding survival probabilities were 11 percent and 0 percent, respectively. This is in addition to the previously reported consistent and significant improvements in overall survival and progression free survival in patients with metastatic pancreatic cancer.


Non-Small Cell Lung Cancer

MPDL3280A Immunotherapy Doubles OS in Patients with Highest Levels of PD-L1


Kidney Cancer

Study: Statins Can Improve Survival in Renal Cell Carcinoma


Stomach Cancer

Avastin Combination Improves Survival in Phase II Study


Endometrial Cancer

Phase III ZoptEC Trial to Continue Following Interim Analysis



APD403 Demonstrates Control Of Nausea and Vomiting After Highly Emetogenic Treatments


Drugs and Targets

FDA Grants Orphan Designation For Reolysin in Malignant Glioma

 NCI CTEP-Approved Trials for the Month of May 
June 2015
April 2015PDF



Keytruda Meets PFS, OS Endpoints in Phase III Advanced Melanoma Trial

A phase III study investigating Keytruda patients with advanced melanoma met two primary endpoints, demonstrating improvements in progression-free survival and overall survival compared to Yervoy. The study’s independent data monitoring committee recommended stopping the trial early.

In the trial, named KEYNOTE-006, Keytruda (pembrolizumab) improved PFS by 42 percent and extended overall survival by 34 percent compared to Yervoy (ipilimumab).

Investigators from 16 countries enrolled 834 patients with metastatic melanoma in the clinical trial, and patients were randomly assigned to Keytruda and Yervoy. The study was published online in the New England Journal of Medicine, and was presented at the annual meeting of the American Association for Cancer Research. The trial was sponsored by Merck.


Prostate Cancer

Three Xtandi Trials Show Positive Results In Castration-Resistant Prostate Cancer

Astellas Pharma Inc. and Medivation Inc. presented an updated overall survival analysis from the placebo-controlled phase III trial of Xtandi in chemotherapy-naive metastatic CRPC.

The companies also published data from two separate phase II head-to-head studies, named STRIVE and TERRAIN, comparing Xtandi (enzalutamide) to Casodex (bicalutamide).

The phase III trial, named PREVAIL, was a randomized, double-blind trial that enrolled 1,717 patients at sites in the U.S., Canada, Europe, Australia, Russia, Israel and Asia, including Japan.


Drugs and Targets

FDA Updates Zytiga Label To Include Chemotherapy-Naive Metastatic CRPC Data

FDA approved a label update for Zytiga (abiraterone acetate) plus prednisone to include overall survival results in chemotherapy-naive men with metastatic castration-resistant prostate cancer.

The update was based on the final analysis of the phase III, randomized, double-blind, placebo-controlled COU-AA-302 study, which showed that Zytiga plus prednisone significantly prolonged median overall survival, compared to placebo plus prednisone. 


Breast Cancer

Ongoing Phase II Trial Shows Correlation Between Immune Response and Recurrence



Circulating Tumor Cells Can Be Used to Detect DLBCL Recurrence, Researchers Say

 NCI CTEP-Approved Trials for the Month of April 
April 2015
March 2015PDF


Phase III Trial of Imbruvica Unblinded Following Significant Increase in PFS

An independent data monitoring committee recommended unblinding the phase III HELIOS trial, which is evaluating Imbruvica in combination with bendamustine and rituximab in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, following clinically meaningful and statistically significant treatment benefit.

The study has met its primary endpoint in extending progression-free survival. The safety profile of Imbruvica combination was consistent with prior clinical experience. Imbruvica is jointly developed and commercialized by Pharmacyclics and Janssen Biotech Inc.

HELIOS, an international, placebo-controlled trial enrolled 578 CLL or SLL patients who had received at least one line of prior systemic therapy. Patients were randomized to receive either Imbruvica orally once daily in combination with six cycles of BR; or placebo orally once daily with six cycles of BR, with treatment continuing until disease progression or unacceptable toxicity.

 Prostate Cancer

Provenge Immune Response Continued For Two Years in Phase II Study in BRPC

Preliminary results from the phase II STAND trial showed a robust immune response with Provenge (sipuleucel-T) that continued two years after completing treatment in men with biochemically-recurrent prostate cancer. 

The STAND study is a randomized trial consisting of two patient study groups. One group completed Provenge two weeks before initiation of androgen deprivation therapy and the second received Provenge three months after the start of ADT.

Preliminary results from STAND indicate that immune responses were observed in both study arms and suggest there may be a greater cellular immune response in patients who received Provenge prior to ADT compared with those who received Provenge following three months of ADT. Humoral immune responses were observed and similar between both treatment arms.

 Drugs and Targets

FDA Grants Accelerated Approval to Farydak for Patients with Multiple Myeloma

FDA granted accelerated approval to Farydak (panobinostat) for the treatment of patients with multiple myeloma.

An improvement in survival or disease-related symptoms has not yet been established for Farydak. The drug’s sponsor, Novartis Pharmaceuticals, is required to conduct confirmatory trials to verify and describe the clinical benefit of Farydak. FDA had previously granted Farydak priority review and orphan product designation.

Farydak inhibits histone deacetylases, which may slow the over-development of plasma cells in multiple myeloma patients or cause these cells to die. Farydak is the first HDAC inhibitor approved to treat multiple myeloma. 

Also: FDA approves Unituxin, the EU approves Jakavi, and more

 Soft Tissue Sarcoma
Phase III Halaven Trial Shows Extended OS over Dacarbazine
 Brain Cancer
Study Shows 73% Survival at Three Years by Combining Radiation Therapy and Chemotherapy
Pacritinib Phase II Study Shows Reduction in Spleen Volume
 NCI CTEP-Approved Trials for the Month of March
March 2015
February 2015PDF


Gazyva Increases PFS in Phase III Trial Of Indolent Non-Hodgkin’s Lymphoma Patients

Patients with indolent non-Hodgkin’s lymphoma lived significantly longer without disease worsening or death when treated with Gazyva (obinutuzumab) plus bendamustine and followed by Gazyva alone, compared to bendamustine alone. 

The phase III trial was stopped by an independent data monitoring committee following a pre-planned interim analysis due to the level of benefit seen in the Gazyva arm compared to the bendamustine arm. The study’s primary endpoint was progression-free survival. There were no unexpected adverse events with Gazyva.


Imbruvica Demonstrates 88% Response Rate In Studies of Relapsed/Refractory CLL Patients

Two independent phase III clinical trials, LUX-Lung 3 and LUX-Lung 6, in epidermal growth factor receptor mutation-positive metastatic non-small cell lung cancer demonstrated positive results in overall survival.

In each trial, patients whose tumors have the most common EGFR mutation—deletion in exon 19—lived more than one year longer when treated with first-line afatinib (Gilotrif) compared to standard chemotherapy. The data was published in The Lancet Oncology.

 Drugs and Targets

FDA Grants Accelerated Approval to Ibrance In HER2-Negative Metastatic Breast Cancer

FDA granted accelerated approval to Ibrance (palbociclib) to treat metastatic breast cancer.

Ibrance inhibits cyclin-dependent kinases 4 and 6, which are involved in promoting the growth of cancer cells. Ibrance is intended for postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer who have not yet received an endocrine-based therapy. It is to be used in combination with letrozole.

Also: FDA approves Lenvima, expands label for Revlimid, and more

 Prostate Cancer
Researchers: Cabazitaxel Functions Differently Than Other Taxanes
 Childhood Cancer
Cranial Irradiation Can Increase Risk of Pituitary Hormone Deficiencies Later in Life, Study Says
Study: Lymphoseek Patients Had Fewer Sentinel Lymph Nodes Removed Per Procedure
 Head and Neck Cancers
TCGA Researchers Discover Genomic Differences in Cancers Caused by Infection
 NCI CTEP-Approved Trials for the Month of February
February 2015
Page 3 of 512345